Preferred Label : Polfermetinib;
NCIt synonyms : MEK Inhibitor PF-07799544;
NCIt definition : An orally bioavailable, brain penetrating inhibitor of mitogen-activated protein kinase
kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration,
polfermetinib specifically targets, binds to and inhibits the catalytic activity of
MEK, thereby inhibiting the activation of MEK-dependent effector proteins, including
extracellular signal-regulated kinase (ERK), and inhibits the proliferation of tumor
cells in which the RAS/RAF/MEK/ERK signaling pathway is overactivated. The threonine/tyrosine
protein kinase MEK plays a key role in the RAS/RAF/MEK/ERK signaling pathway, which
is frequently upregulated in a variety of tumor cell types and regulates key cellular
activities including cell growth, proliferation, survival, differentiation and apoptosis.;
UNII : GST8GSH94B;
CAS number : 2845151-86-0;
Molecule name : ARRY-134; PF 07799544; ARRY 134; PF-07799544;
NCI Metathesaurus CUI : CL1912932;
Origin ID : C192683;
UMLS CUI : C5787279;
Semantic type(s)
- concept_is_in_subset
- has_target
